Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
The STEP 4 trial showed participants regaining approximately two-thirds of lost weight within one year of stopping medication
The 72-hour minimum gives your body time to clear enough of the previous dose to avoid excessive peak concentrations
Experience you can trust Our team has performed thousands of collagen-inducing treatments with advanced protocols tailored to every skin type
A glutathione injection by a registered nurse Available on its own or as an add-on Quick and convenient In-home service How It Works Getting an IV at home is simple
US$ 21.84
US$ 26.87
US$ 23.11
